Antigenic variation in gp120s from molecular clones of HIV-1 LAI.

To address the relationship between primary sequence variation in HIV-1 gp120 and its antigenic structure in a simple system, we have measured the binding of human and murine monoclonal antibodies (MAbs) to gp120 from four molecular clones of HIV-1 LAI: HxB2, HxB3, Hx10, and NL4-3. Despite the close relationship between these clones, and their relatively conserved gp120 sequences, there is considerable variation in their antigenic structure, judged by MAb reactivities to the V2, V3, and C4 domains and to discontinuous epitopes. Because of our prior studies of the determinants of MAb binding to HxB2 gp120, we can make reasonable estimates of how sequence variation among the LAI clone gp120s affects their binding of some MAbs; for other MAbs our current knowledge of gp120 structure is too limited to allow such estimates. These results indicate that small variations in primary gp120 amino acid sequence can profoundly affect recognition of this glycoprotein by all five groups of defined anti-gp120 neutralizing antibodies.

[1]  M. Robert-Guroff,et al.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.

[2]  J. Sodroski,et al.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. , 1985, Science.

[3]  Robin A. Weiss,et al.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.

[4]  M. Gonda,et al.  Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. , 1985, Science.

[5]  Olivier Danos,et al.  Nucleotide sequence of the AIDS virus, LAV , 1985, Cell.

[6]  Mark L. Pearson,et al.  Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.

[7]  E. Reddy,et al.  HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients , 1985, Cell.

[8]  Robin A. Weiss,et al.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.

[9]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[10]  A. Dalgleish,et al.  Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.

[11]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.

[12]  V. Tkachuk,et al.  Morphological alterations in endothelial cells from human aorta and umbilical vein induced by forskolin and phorbol 12-myristate 13-acetate: a synergistic action of adenylate cyclase and protein kinase C activators. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A J Langlois,et al.  HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. , 1986, Science.

[14]  L. Arthur,et al.  Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J K Nicholson,et al.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. , 1986, Science.

[16]  L. Jagodzinski,et al.  Complete nucleotide sequences of functional clones of the AIDS virus. , 1987, AIDS research and human retroviruses.

[17]  G. Shaw,et al.  Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions , 1987, Journal of virology.

[18]  R. Weiss,et al.  Neutralizing monoclonal antibodies to the AIDS virus. , 1988, AIDS.

[19]  J. Goudsmit Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. , 1988, AIDS (London).

[20]  H. Lyerly,et al.  Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. , 1988, AIDS research and human retroviruses.

[21]  S. Matsushita,et al.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope , 1988, Journal of virology.

[22]  J. Cohen,et al.  Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120. , 1989, Journal of immunology.

[23]  T. H. Lee,et al.  Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.

[24]  Linear versus conformational variation of V3 neutralization domains of HIV‐1 during experimental and natural infection , 1989, AIDS.

[25]  J. Moore,et al.  An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. , 1989, AIDS.

[26]  A J Langlois,et al.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Profy,et al.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.

[28]  M. Reitz,et al.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope , 1990, Journal of virology.

[29]  J. Davide,et al.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. , 1990, Science.

[30]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[31]  J. Moore,et al.  Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. , 1990, AIDS.

[32]  R. Gallo,et al.  Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees , 1990, Journal of virology.

[33]  J. Moore,et al.  Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro. , 1990, AIDS research and human retroviruses.

[34]  M. Champe,et al.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.

[35]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[36]  N. Haigwood,et al.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Moore,et al.  The role of the V3 loop of gp120 in HIV infection. , 1991, AIDS.

[38]  D. Ho,et al.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Ho,et al.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.

[40]  K. Steimer,et al.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. , 1991, Science.

[41]  J. Goudsmit,et al.  Neutralization of HIV‐1: a paradox of humoral proportions , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  J. Sodroski,et al.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.

[43]  R. Cheynier,et al.  LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. , 1991, Science.

[44]  G. Pauli,et al.  Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. , 1992, The Journal of general virology.

[45]  J. Sodroski,et al.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.

[46]  K. Steimer,et al.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons , 1992, Journal of virology.

[47]  D. Ho,et al.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.

[48]  W. Morrow,et al.  Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. , 1992, Journal of immunology.

[49]  J. Sodroski,et al.  Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region , 1992, Journal of virology.

[50]  G. Nakamura,et al.  Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1 , 1993, Journal of virology.

[51]  G K Lewis,et al.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop , 1993, Journal of virology.

[52]  J. Sodroski,et al.  Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.

[53]  J. Hansen,et al.  Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. , 1993, The Journal of general virology.

[54]  Q. Sattentau,et al.  Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains , 1993, Journal of virology.

[55]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[56]  P. Westervelt,et al.  Structure—function relationships of the HIV‐1 envelope V3 loop tropism determinant: evidence for two distinct conformations , 1993, AIDS.

[57]  J. Moore,et al.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.